Related Experiment Video

Updated: Jun 18, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer

Yanal M Murad1, Timothy M Clay

  • 1Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 10, 2009
PubMed

Insights

Toll-like receptor 9 (TLR9) agonists, like CpG oligodeoxynucleotides (ODNs), show promise in activating immune responses against cancer. Clinical trials are evaluating their efficacy in treating various cancers, alone or with other therapies.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptors (TLRs) are key components of the innate immune system, recognizing conserved microbial patterns.
  • TLR9 specifically binds unmethylated CpG motifs, making it a therapeutic target for immune activation.
  • Activation of TLR9 stimulates dendritic cells and B cells, promoting T helper-1 (Th1) immune responses.

Purpose of the Study:

  • To review the therapeutic potential of CpG oligodeoxynucleotides (ODNs) as TLR9 agonists.
  • To discuss the application of CpG ODNs in cancer treatment and as vaccine adjuvants.
  • To summarize findings from Phase I and II clinical trials involving TLR9 agonists.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of TLR9 agonist mechanisms of action.
  • Evaluation of safety and efficacy data from clinical studies.

Main Results:

  • CpG ODNs activate potent immune responses, including antitumor effects in preclinical models and patients.
  • CpG ODNs demonstrate efficacy as vaccine adjuvants and in combination cancer immunotherapy.
  • Several TLR9 agonists are in clinical trials for hematologic and solid tumors, including NHL, renal cell carcinoma, melanoma, and non-small cell lung cancer.

Conclusions:

  • TLR9 agonists, particularly CpG ODNs, represent a promising therapeutic strategy for various cancers.
  • CpG ODNs have shown potential in enhancing immune responses and are being actively investigated in clinical trials.
  • Further research and clinical evaluation are ongoing to establish the full therapeutic benefit of TLR9 agonists in oncology.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...